» Authors » Catherine C OConnor

Catherine C OConnor

Explore the profile of Catherine C OConnor including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 46
Citations 395
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Munari S, Wilkinson A, Asselin J, Owen L, Read P, Finlayson R, et al.
Sex Health . 2024 Feb; 21. PMID: 38369757
Background: Chlamydia remains the most notified bacterial sexually transmissible infection in Australia with guidelines recommending testing for re-infection at 3months post treatment. This paper aimed to determine chlamydia retesting and...
2.
Heron J, McManus H, Vickers T, Ryan K, Wright E, Carter A, et al.
PLoS One . 2023 Feb; 18(2):e0280339. PMID: 36827395
Background: Tenofovir disoproxil fumarate (TDF) is associated with adverse renal outcomes when prescribed for HIV infection. There are few data concerning real-world renal outcomes amongst patients prescribed TDF for pre-exposure...
3.
Wong H, Wang P, Sun Y, Newman C, Vujcich D, Vaughan C, et al.
Cult Health Sex . 2021 Dec; 25(1):1-17. PMID: 34941479
Translated questionnaires are increasingly used in population health research. Nevertheless, translation is often not conducted with the same rigour as the process of survey development in the original language. This...
4.
Wong H, Jin D, Wang P, Sun Y, Mao L, Zhang Y, et al.
Qual Health Res . 2021 Oct; 31(14):2757-2769. PMID: 34636281
Videoconferencing focus groups have emerged as a popular method for collecting qualitative data. However, its use in sexual and reproductive health research is still very much in its infancy. Based...
5.
Drak D, McManus H, Vickers T, Heron J, Vaccher S, Zablotska I, et al.
AIDS . 2021 Jul; 35(14):2319-2326. PMID: 34310371
Background: HIV preexposure prophylaxis (PrEP) with fixed-dose tenofovir disoproxil fumarate (TDF) and emtricitabine has been associated with low rates of renal impairment in clinical trials. Large-scale PrEP implementation may result...
6.
Whitford K, Callander D, Watchirs Smith L, Guy R, Kong M, Ward J, et al.
Sex Transm Dis . 2019 Dec; 47(1):34-40. PMID: 31856073
Background: In recent years, gonorrhea notifications have increased in women in Australia and other countries. We measured trends over time and risk factors among Australian Aboriginal and Torres Strait Islander...
7.
Turner D, Drak D, OConnor C, Templeton D, Gracey D
AIDS Res Ther . 2019 Dec; 16(1):40. PMID: 31810490
Background: Tenofovir disoproxil fumarate (TDF) is widely used in the management of HIV-infection, but has been associated with renal impairment in a small proportion of patients. Tenofovir alafenamide (TAF), a...
8.
Heron J, Norman S, Yoo J, Lembke K, OConnor C, Weston C, et al.
PLoS One . 2019 Oct; 14(10):e0223224. PMID: 31596867
Background: Non-AIDS-related mortality rates among HIV-infected patients still exceed those of their uninfected peers. A major driver of this excess mortality is a higher risk of non-infectious comorbidities, including cardiovascular...
9.
McManus H, Callander D, Donovan B, Russell D, OConnor C, Davies S, et al.
Med J Aust . 2019 Feb; 210(6):269-275. PMID: 30773651
Objectives: To determine trends in and predictors of early treatment for people newly diagnosed with human immunodeficiency virus (HIV) infection in Australia. Design, Setting: Retrospective cohort analysis of routinely collected...
10.
Drak D, Barratt H, Templeton D, OConnor C, Gracey D
PLoS One . 2019 Jan; 14(1):e0210106. PMID: 30653509
Background: Pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) significantly reduces the risk of HIV acquisition. TDF is a known nephrotoxin however, renal dysfunction from TDF is mostly reversible following...